XML 78 R57.htm IDEA: XBRL DOCUMENT v3.22.2.2
Intangible Assets - Narrative (Details) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 9 Months Ended
Jul. 31, 2022
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Jul. 01, 2022
Acquired Finite-Lived Intangible Assets [Line Items]            
Amortization expense   $ 15.6 $ 0.0 $ 16.8 $ 0.0  
Finite-lived intangible asset, expected amortization, remainder of fiscal year   15.6   15.6    
Finite-lived intangible asset, expected amortization, year one   62.0   62.0    
Finite-lived intangible asset, expected amortization, year two   62.0   62.0    
Finite-lived intangible asset, expected amortization, year three   62.0   62.0    
Finite-lived intangible asset, expected amortization, year four   62.0   62.0    
Finite-lived intangible asset, expected amortization, year five   $ 62.0   $ 62.0    
Sanofi            
Acquired Finite-Lived Intangible Assets [Line Items]            
Up-front payment to collaborating party $ 900.0          
Sanofi Collaboration Agreement, Amended and Restated Immuno-oncology License and Collaboration Agreement            
Acquired Finite-Lived Intangible Assets [Line Items]            
Other liabilities           $ 241.0